Showing 941-950 of 19239 results for "".
Targeting Psoriasis at the Source: New Evidence for Interferon Receptor Therapies
https://reachmd.com/programs/dermconsult/psoriasis-interferon-receptor-therapy/39675/Global Perspectives on Perioperative Immunotherapy in LA HNSCC
https://reachmd.com/programs/cme/global-perspectives-on-perioperative-immunotherapy-in-la-hnscc/36261/Global Perspectives on Perioperative Immunotherapy in LA HNSCCInnovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
https://reachmd.com/programs/cme/innovative-approaches-to-managing-ckm-syndrome-and-hfmrefhfpef/29912/CKM syndrome and HFmrEF/HFpEF present a rising global burden. Tune in to explore emerging therapies with a proven impact on outcomes.Targeting Mixed Hyperlipidemia with APOC3 Inhibition
https://reachmd.com/programs/cme/targeting-mixed-hyperlipidemia-with-apoc3-inhibition/33227/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.Real-World Impact of Evolocumab on MACE Reduction in ASCVD
https://reachmd.com/clinical-practice/cardiology/real-world-impact-of-evolocumab-on-mace-reduction-in-ascvd/39991/Review real-world data on evolocumab and its association with reduced MACE in patients with established atherosclerotic cardiovascular disease.New Insights in the Management of HCM: Exploring the Clinical Spectrum
https://reachmd.com/programs/cme/new-insights-in-the-management-of-hcm-exploring-the-clinical-spectrum/33026/Explore personalized strategies in obstructive HCM, from diagnosis to treatment evolution, including real-world insights into cardiac myosin inhibitor use.CETP Inhibition With Obicetrapib: Implications for Cardiovascular Event Prevention
https://reachmd.com/clinical-practice/cardiology/cetp-inhibition-with-obicetrapib-implications-for-cardiovascular-event-prevention/37124/CETP Inhibition with Obicetrapib: Implications for Cardiovascular Event PreventionWhen Topicals Fail: The New IPC Consensus Every Clinician Should Know
https://reachmd.com/programs/cme/when-topicals-fail-the-new-ipc-consensus-every-clinician-should-know/39967/Review IPC’s 2025 consensus guidance on reclassifying psoriasis severity and redefining failure of topical therapies.From Pixels to Practice: Advancing HCM Care With Multimodality Imaging
https://reachmd.com/programs/cme/from-pixels-to-practice-advancing-hcm-care-with-multimodality-imaging/39877/Explore how multimodality imaging advances diagnosis, treatment selection, and monitoring in hypertrophic cardiomyopathy care.APOC3 Inhibition: New Frontiers Managing Patients with FCS & SHTG
https://reachmd.com/programs/cme/apoc3-inhibition-new-frontiers-managing-patients-with-fcs-shtg/20307/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.